# Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial.

> PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41780559-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41780559-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41780559-semaglutide-v1.json
- Content SHA-256: `4151335d2e2fbd835fef528338dd62d97b613006dc5f7eab1365af224909b3de`

## Claims and source pins

### Headline

Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

### Summary

PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

### Paragraph 1

PubMed lists PMID 41780559 in European heart journal as Journal Article, with publication-date metadata of 2026-07-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`](#source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79))

## Sources

<a id="source-pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79"></a>
- **Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial. · retained source version 1:2026-07-26:current:3133e70acd79edb4b7f07f32ba5182143ff7ffe3cf69f13ad7a4ad7ff788b5a9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41780559/) (`pubmed-observation-pmid-41780559-2026-07-26-3133e70acd79`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41780559-semaglutide-v1.json SHA-256: 4151335d2e2fbd835fef528338dd62d97b613006dc5f7eab1365af224909b3de.